{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:05:13Z","timestamp":1792695913921,"version":"4.5.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["THY-CANC 2022_03_08_03"],"award-info":[{"award-number":["THY-CANC 2022_03_08_03"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ando.2023.03.009","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T12:40:46Z","timestamp":1679488846000},"page":"374-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Endocrine-related adverse conditions induced by tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1534-8216","authenticated-orcid":false,"given":"Simone","family":"De Leo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Moneta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2023.03.009_bib0635","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib0640","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001\u20132020)","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0645","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: multi-targeted or single-targeted?","volume":"2","author":"Broekman","year":"2011","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0650","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2019.05.004","article-title":"Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma","volume":"77","author":"Rimassa","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ando.2023.03.009_bib0655","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","article-title":"Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer","volume":"46","author":"Cabanillas","year":"2019","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0660","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2020.04.021","volume":"134","author":"Sch\u00f6ffski","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib0665","series-title":"Common terminology criteria for adverse events (CTCAE) version 5.0","author":"National Cancer Institute","year":"2017"},{"key":"10.1016\/j.ando.2023.03.009_bib0670","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/EJE-20-0683","article-title":"Therapy of endocrine disease: endocrine-metabolic effects of treatment with multikinase inhibitors","volume":"184","author":"Fallahi","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.009_bib0675","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ando.2018.07.005","article-title":"Endocrine side effects of new anticancer therapies: overall monitoring and conclusions","volume":"79","author":"Castinetti","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2023.03.009_bib0680","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"Desai","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ando.2023.03.009_bib0875","doi-asserted-by":"crossref","first-page":"R91","DOI":"10.1530\/EJE-14-0198","article-title":"Endocrine side effects of anticancer drugs: thyroid effects of tyrosine kinase inhibitors","volume":"171","author":"Illouz","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.009_bib0880","first-page":"723","article-title":"Thyroid dysfunctions induced by tyrosine kinase inhibitors","volume":"13","author":"Fallahi","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ando.2023.03.009_bib0885","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3109\/0284186X.2012.752579","article-title":"Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis","volume":"52","author":"Funakoshi","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0890","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1210\/jc.2016-4025","article-title":"Sorafenib-induced changes in thyroid hormone levels in patients treated for hepatocellular carcinoma","volume":"102","author":"Beukhof","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.009_bib0895","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-08-0648","article-title":"Tyrosine kinase inhibitors and modifications of thyroid function tests: a review","volume":"160","author":"Illouz","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.009_bib0900","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/thy.2017.0579","article-title":"Risk factors for new hypothyroidism during tyrosine kinase inhibitor therapy in advanced non-thyroidal cancer patients","volume":"28","author":"Lechner","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2023.03.009_bib0905","doi-asserted-by":"crossref","DOI":"10.1007\/s11523-023-00951-z","article-title":"Analysis of anti-angiogenesis-related adverse events associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in patients with metastatic renal cell carcinoma","author":"Lee","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0910","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1586\/14737140.2014.929501","article-title":"Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis","volume":"14","author":"Abdel-Rahman","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ando.2023.03.009_bib0685","doi-asserted-by":"crossref","DOI":"10.1007\/s11523-023-00951-z","article-title":"Analysis of anti-angiogenesis-related adverse events associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in patients with metastatic renal cell carcinoma","author":"Lee","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0690","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.esmoop.2021.100105","article-title":"ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups","volume":"6","author":"Quinn","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ando.2023.03.009_bib0695","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000499089","article-title":"Axitinib-induced hypothyroidism as a predictor of long-term survival in patients with metastatic renal cell carcinoma","volume":"102","author":"Takada","year":"2019","journal-title":"Urol Int."},{"key":"10.1016\/j.ando.2023.03.009_bib0700","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.ejca.2011.07.014","article-title":"Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma","volume":"47","author":"Tomita","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib0705","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0710","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0715","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41591-020-01193-6","article-title":"Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial","volume":"27","author":"Fisher","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ando.2023.03.009_bib0720","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/jamaoncol.2022.0238","article-title":"Cabozantinib as first-line treatment in patients with metastatic collecting duct renal cell carcinoma: results of the BONSAI trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)","volume":"8","author":"Procopio","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0725","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/COC.0000000000000478","article-title":"Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: real-world data from an italian managed access program","volume":"42","author":"Prisciandaro","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ando.2023.03.009_bib0730","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.03.009_bib0735","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer","volume":"22","author":"Schlumberger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ando.2023.03.009_bib0740","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2023.03.009_bib0745","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/hepr.13427","article-title":"Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: a multicenter analysis with propensity score matching","volume":"50","author":"Tada","year":"2020","journal-title":"Hepatol Res"},{"key":"10.1016\/j.ando.2023.03.009_bib0750","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1507\/endocrj.EJ19-0140","article-title":"Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma","volume":"66","author":"Koizumi","year":"2019","journal-title":"Endocr J"},{"key":"10.1016\/j.ando.2023.03.009_bib0755","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.3390\/cancers12113078","article-title":"Hypothyroidism is a predictive factor for better clinical outcomes in patients with advanced hepatocellular carcinoma undergoing lenvatinib therapy","volume":"12","author":"Shomura","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ando.2023.03.009_bib0760","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/thy.2010.0251","article-title":"Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia","volume":"20","author":"Kim","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2023.03.009_bib0765","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.03.009_bib0770","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.ejca.2013.06.003","article-title":"Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies","volume":"49","author":"Matrana","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib0775","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ijc.33238","article-title":"First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial","volume":"148","author":"Staehler","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib0780","doi-asserted-by":"crossref","first-page":"6755","DOI":"10.2147\/CMAR.S323499","article-title":"Real-world outcome and prognostic factors of pazopanib in advanced soft tissue sarcoma","volume":"13","author":"Alshamsan","year":"2021","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ando.2023.03.009_bib0785","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1177\/1078155220904138","article-title":"The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: a retrospective cross-sectional study of a Turkish cohort","volume":"26","author":"Karaa\u011fa\u00e7","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.ando.2023.03.009_bib0790","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.ejca.2013.05.028","article-title":"Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study","volume":"49","author":"Bruix","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib0795","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1530\/EJE-17-0231","article-title":"Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?","volume":"177","author":"Pani","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.009_bib0800","doi-asserted-by":"crossref","first-page":"45703","DOI":"10.1038\/srep45703","article-title":"Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: the TRIBUTE analysis","volume":"7","author":"Giampieri","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ando.2023.03.009_bib0805","first-page":"4059","article-title":"Investigation of regorafenib-induced hypothyroidism in patients with metastatic colorectal cancer","volume":"35","author":"Sugita","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ando.2023.03.009_bib0810","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11523-019-00672-2","article-title":"Regorafenib-induced hypothyroidism as a predictive marker for improved survival in metastatic or unresectable colorectal cancer refractory to standard therapies: a prospective single-center study","volume":"14","author":"Kim","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0815","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/onco.13755","article-title":"An underdiagnosed hypothyroidism and its clinical significance in patients with advanced hepatocellular carcinoma","volume":"26","author":"Shao","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ando.2023.03.009_bib0820","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jjco\/hyt054","article-title":"Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized phase 3 AXIS trial","volume":"43","author":"Ueda","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0825","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial","volume":"14","author":"Hutson","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0830","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.urolonc.2009.08.011","article-title":"Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation","volume":"28","author":"Miyake","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0835","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JGO.19.00111","article-title":"Efficacy and prognostic factors of sunitinib as first-line therapy for patients with metastatic renal cell carcinoma in an Arab population","volume":"6","author":"Badran","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0840","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/jjco\/hyv045","article-title":"Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients","volume":"45","author":"Akaza","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0845","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0850","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1055\/a-1658-3077","article-title":"Sunitinib-induced hypothyroidism and survival in pancreatic neuroendocrine tumors","volume":"53","author":"Mathew","year":"2021","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.ando.2023.03.009_bib0855","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/ERC-19-0259","article-title":"Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response","volume":"27","author":"Valerio","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib0860","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0865","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.3390\/cancers14143405","article-title":"Treatment of RET-positive advanced medullary thyroid cancer with multi-tyrosine kinase inhibitors\u00a0\u2013\u00a0a retrospective multicenter registry analysis","volume":"14","author":"Koehler","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ando.2023.03.009_bib0870","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1210\/jc.2009-2461","article-title":"Vandetanib (100\u00a0mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"95","author":"Robinson","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.009_bib0915","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.bjc.6606029","article-title":"The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma","volume":"104","author":"Shinohara","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib0920","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jjco\/hys076","article-title":"Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma","volume":"42","author":"Daimon","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib0925","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.semcancer.2020.12.008","article-title":"Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism","volume":"79","author":"Basolo","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ando.2023.03.009_bib0930","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2019.05.015","article-title":"Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders","volume":"141","author":"Jannin","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ando.2023.03.009_bib0935","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/thy.2012.0456","article-title":"Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis","volume":"23","author":"Makita","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2023.03.009_bib0940","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/thy.2015.0170","article-title":"Thyroid dysfunction in patients with metastatic carcinoma treated with sunitinib: is thyroid autoimmunity involved?","volume":"25","author":"Pani","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2023.03.009_bib0945","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/thy.2009.0414","article-title":"Sunitinib induces hypothyroidism with a markedly reduced vascularity","volume":"20","author":"Makita","year":"2010","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ando.2023.03.009_bib0950","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/thy.2009.0125","article-title":"Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?","volume":"20","author":"Rogiers","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2023.03.009_bib0955","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.ejrad.2011.06.035","article-title":"Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function","volume":"81","author":"Kitajima","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ando.2023.03.009_bib0960","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/thy.2012.0378","article-title":"Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib","volume":"23","author":"Ohba","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2023.03.009_bib0965","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1349-7006.2009.01465.x","article-title":"Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients","volume":"101","author":"Mukohara","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ando.2023.03.009_bib0970","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1089\/thy.2013.0621","article-title":"Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma","volume":"24","author":"Yavuz","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2023.03.009_bib0975","first-page":"481","article-title":"Sunitinib-induced thyrotoxicosis\u00a0\u2013\u00a0a not so rare entity","volume":"35","author":"Jazvi\u0107","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ando.2023.03.009_bib0980","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1186\/s12885-016-2705-3","article-title":"Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma","volume":"16","author":"Eroukhmanoff","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib0985","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/thy.2006.0308","article-title":"Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity","volume":"17","author":"Wong","year":"2007","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2023.03.009_bib0990","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","article-title":"A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake","volume":"92","author":"Mannavola","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.009_bib0995","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1179\/1973947815Y.0000000039","article-title":"Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?","volume":"28","author":"Bozkurt","year":"2016","journal-title":"J Chemother"},{"key":"10.1016\/j.ando.2023.03.009_bib1000","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cncr.25422","article-title":"Hypothyroidism in patients with renal cell carcinoma: blessing or curse?","volume":"117","author":"Schmidinger","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib1005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12032-017-0928-z","article-title":"Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients","volume":"34","author":"Buda-Nowak","year":"2017","journal-title":"Med Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib1010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/s12885-019-5610-8","article-title":"Impact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer","volume":"19","author":"Vasileiadis","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib1015","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib1020","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00345-010-0627-2","article-title":"Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib","volume":"29","author":"Riesenbeck","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.ando.2023.03.009_bib1025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/CMAR.S232823","article-title":"Anorexia, hypertension, pneumothorax, and hypothyroidism: potential signs of improved clinical outcome following apatinib in advanced osteosarcoma","volume":"12","author":"Xie","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ando.2023.03.009_bib1030","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1089\/thy.2017.0587","article-title":"Hypothyroidism during tyrosine kinase inhibitor therapy is associated with longer survival in patients with advanced non-thyroidal cancers","volume":"28","author":"Lechner","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2023.03.009_bib1035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clpt.2005.06.010","article-title":"Imatinib induces hypothyroidism in patients receiving levothyroxine","volume":"78","author":"de Groot","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ando.2023.03.009_bib1040","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ctrv.2018.04.007","article-title":"Management of treatment-related toxicities in advanced medullary thyroid cancer","volume":"66","author":"Brose","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ando.2023.03.009_bib1045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/ERC-19-0259","article-title":"Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response","volume":"27","author":"Valerio","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib1050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"Motesanib diphosphate in progressive differentiated thyroid cancer","volume":"359","author":"Sherman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.03.009_bib1055","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ando.2023.03.009_bib1060","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1530\/ERC-15-0252","article-title":"Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer","volume":"22","author":"Worden","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib1065","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1210\/jc.2009-2507","article-title":"Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination","volume":"95","author":"Abdulrahman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.009_bib1070","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1308893","article-title":"Thyroid hormone inactivation in gastrointestinal stromal tumors","volume":"370","author":"Maynard","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.03.009_bib1075","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/jc.2011-1172","article-title":"Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression","volume":"96","author":"Kappers","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.009_bib1080","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1530\/EJE-08-0006","article-title":"Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients","volume":"158","author":"Dora","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.009_bib1085","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1210\/jc.2011-1837","article-title":"Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport","volume":"97","author":"Braun","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.009_bib1090","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/EJE-12-0828","article-title":"Sorafenib therapy decreases the clearance of thyrotropin","volume":"168","author":"Verloop","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.009_bib1095","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.03.009_bib1100","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ando.2018.07.003","article-title":"Expert opinion on thyroid complications of new anti-cancer therapies: tyrosine kinase inhibitors","volume":"79","author":"Drui","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2023.03.009_bib1105","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ando.2023.03.009_bib1110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1634\/theoncologist.12-1-107","article-title":"Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma","volume":"12","author":"Rock","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ando.2023.03.009_bib1115","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/cancers14030593","article-title":"Endocrine toxicities of antineoplastic therapy: the adrenal topic","volume":"14","author":"Barnabei","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ando.2023.03.009_bib1120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1742-1241.2008.01856.x","article-title":"Is there any relationship between imatinib mesylate medication and hypothalamic-pituitary-adrenal axis dysfunction?","volume":"64","author":"Bilgir","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ando.2023.03.009_bib1125","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/jc.2018-01836","article-title":"Primary adrenal insufficiency during lenvatinib or vandetanib and improvement of fatigue after cortisone acetate therapy","volume":"104","author":"Colombo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.009_bib1130","first-page":"46","article-title":"Cortisol deficiency in lenvatinib treatment of thyroid cancer: an underestimated common adverse event","volume":"32","author":"Monti","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2023.03.009_bib1135","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-023-02025-3","article-title":"Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test","author":"Valerio","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ando.2023.03.009_bib1140","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1210\/jc.2010-2771","article-title":"Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer","volume":"96","author":"Brassard","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.009_bib1145","article-title":"Tyrosine Kinase inhibitors\u2019 newly reported endocrine side effect: pazopanib-induced primary adrenal insufficiency in a patient with metastatic renal cell cancer","volume":"8","author":"Elshimy","year":"2020","journal-title":"J Investig Med High Impact Case Rep"},{"key":"10.1016\/j.ando.2023.03.009_bib1150","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/0192623308326151","article-title":"Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors","volume":"36","author":"Patyna","year":"2008","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.ando.2023.03.009_bib1155","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40618-014-0133-2","article-title":"Pituitary side effects of old and new drugs","volume":"37","author":"Zatelli","year":"2014","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ando.2023.03.009_bib1160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","article-title":"Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"11","author":"Caldemeyer","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.ando.2023.03.009_bib1165","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1172\/JCI60417","article-title":"EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas","volume":"121","author":"Fukuoka","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2023.03.009_bib1170","doi-asserted-by":"crossref","first-page":"39297","DOI":"10.1074\/jbc.M111.243493","article-title":"In vivo evidence for epidermal growth factor receptor (EGFR)-mediated release of prolactin from the pituitary gland","volume":"286","author":"Dahlhoff","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ando.2023.03.009_bib1175","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1345\/aph.1L410","article-title":"Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib","volume":"42","author":"Liapis","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ando.2023.03.009_bib1180","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/17843286.2018.1476115","article-title":"Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies","volume":"74","author":"Bastin","year":"2019","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.ando.2023.03.009_bib1185","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14737140.2019.1609355","article-title":"Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?","volume":"19","author":"Afshar","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ando.2023.03.009_bib1190","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/cncr.28089","article-title":"Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients","volume":"119","author":"Weickhardt","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib1195","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s10815-021-02181-6","article-title":"Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review","volume":"38","author":"Rambhatla","year":"2021","journal-title":"J Assist Reprod Genet"},{"key":"10.1016\/j.ando.2023.03.009_bib1200","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.03.009_bib1205","doi-asserted-by":"crossref","first-page":"R247","DOI":"10.1530\/ERC-12-0400","article-title":"Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies","volume":"21","author":"Alem\u00e1n","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib1210","doi-asserted-by":"crossref","first-page":"e34914","DOI":"10.1371\/journal.pone.0034914","article-title":"Dasatinib as a bone-modifying agent: anabolic and antiresorptive effects","volume":"7","author":"Garcia-Gomez","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ando.2023.03.009_bib1215","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1002\/cncr.26435","article-title":"Sunitinib-induced hyperparathyroidism: a possible mechanism to altered bone homeostasis","volume":"118","author":"Baldazzi","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2023.03.009_bib1220","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1089\/thy.2022.0439","article-title":"Hypocalcemia during lenvatinib treatment for advanced thyroid cancer: clinical features and management in a real-life setting","volume":"33","author":"De Leo","year":"2023","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2023.03.009_bib1225","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ando.2018.07.011","article-title":"Expert opinion on the metabolic complications of new anticancer therapies: tyrosine kinase inhibitors","volume":"79","author":"Buffier","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2023.03.009_bib1230","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1038\/bcj.2012.30","article-title":"Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy","volume":"2","author":"Deangelo","year":"2012","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ando.2023.03.009_bib1235","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa1413654","article-title":"Rociletinib in EGFR-mutated non-small-cell lung cancer","volume":"372","author":"Sequist","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.03.009_bib1240","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40264-016-0485-y","article-title":"Hyperglycaemia induced by novel anticancer agents: an undesirable complication or a potential therapeutic opportunity?","volume":"40","author":"Shah","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.ando.2023.03.009_bib1245","first-page":"249","article-title":"Understanding, recognizing, and managing toxicities of targeted anticancer therapies","volume":"63","author":"Dy","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ando.2023.03.009_bib1250","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1056\/NEJMc052500","article-title":"Imatinib and hyperlipidemia","volume":"353","author":"Gottardi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.03.009_bib1255","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ando.2023.03.009_bib1260","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/ajco.12473","article-title":"A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma","volume":"12","author":"Song","year":"2016","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426623000501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426623000501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:54:35Z","timestamp":1757717675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426623000501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":126,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0003426623000501"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2023.03.009","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocrine-related adverse conditions induced by tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2023.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}